Nantahala Capital Management’s Tango Therapeutics TNGX Stock Holding History

Nantahala Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26.2M	Sell	1,250,452 -2,322,181	-65%	-$32.3M	0.96%	24
2025 Q4	$31.7M	Buy	3,572,633 +1,762,685	+97%	+$15.2M	1.05%	21
2025 Q3	$15.2M	Sell	1,809,948 -1,629,646	-47%	-$11M	0.53%	46
2025 Q2	$17.6M	Buy	3,439,594 +451,611	+15%	+$1.12M	0.69%	32
2025 Q1	$4.09M	Buy	2,987,983 +183,573	+7%	+$451K	0.16%	80
2024 Q4	$8.67M	Buy	+2,804,410	New	+$13M	0.37%	51
2022 Q2	–	Sell	-98,794	Closed	-$749K	–	131
2022 Q1	$749K	Sell	98,794 -1,206	-1%	-$10.5K	0.03%	104
2021 Q4	$1.09M	Hold	100,000	–	–	0.04%	119
2021 Q3	$1.29M	Buy	+100,000	New	+$1.2M	0.04%	113
2021 Q2	–	Sell	-175,915	Closed	-$1.96M	–	131
2021 Q1	$1.96M	Sell	175,915 -24,085	-12%	-$277K	0.06%	100
2020 Q4	$2.29M	Hold	200,000	–	–	0.07%	99
2020 Q3	$2.07M	Buy	+200,000	New	+$2.04M	0.06%	97

Other funds holding TNGX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Nantahala Capital Management's TNGX Position: Q1 2026 in Review

Nantahala Capital Management reduced its Tango Therapeutics (TNGX) stake by 65% in Q1 2026, selling an estimated $32.3M and leaving 1,250,452 shares worth $26.2M. The position accounts for 0.96% of the portfolio, ranked #24.

Nantahala Capital Management first reported a position in TNGX in Q3 2020 and has held it in 12 quarters since. The position peaked at $31.7M in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

Nantahala Capital Management held 1,250,452 shares of Tango Therapeutics worth $26.2M as of Q1 2026.
Nantahala Capital Management sold 2,322,181 Tango Therapeutics shares in Q1 2026, an estimated $32.3M.
Tango Therapeutics made up 0.96% of Nantahala Capital Management's portfolio in Q1 2026, its #24 holding.
Nantahala Capital Management first reported a position in Tango Therapeutics in Q3 2020 and has held it in 12 quarters since.
Nantahala Capital Management's Tango Therapeutics position peaked at $31.7M in Q4 2025.
194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.